



(11) **EP 3 363 797 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 2 (W2 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
10.03.2021 Bulletin 2021/10

(45) Date of publication and mention
of the grant of the patent:
02.12.2020 Bulletin 2020/49

(21) Application number: **17208659.7**

(22) Date of filing: **12.07.2010**

(51) Int Cl.:
C07D 401/12 ^(2006.01) **C07D 401/14** ^(2006.01)
C07D 407/14 ^(2006.01) **C07D 413/14** ^(2006.01)
C07D 471/04 ^(2006.01) **C07D 491/048** ^(2006.01)
A61K 31/437 ^(2006.01) **A61K 31/4439** ^(2006.01)
A61K 31/444 ^(2006.01) **A61K 31/497** ^(2006.01)
A61K 31/506 ^(2006.01) **A61P 9/00** ^(2006.01)
A61P 25/28 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 37/00 ^(2006.01) **A61K 31/585** ^(2006.01)
A61K 31/5377 ^(2006.01) **A61K 31/496** ^(2006.01)
A61K 31/4709 ^(2006.01) **A61K 45/06** ^(2006.01)

(54) **ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS**
ORALE DARREICHUNGSFORM VON APOPTOSESIGNALREGULIERENDE KINASEHEMMERN
FORME DE DOSAGE ORALE D'INHIBITEURS DE KINASE RÉGULANT LE SIGNAL D'APOPTOSE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR

(30) Priority: **13.07.2009 US 225076 P**
13.07.2009 US 225079 P
22.12.2009 US 289263 P

(43) Date of publication of application:
22.08.2018 Bulletin 2018/34

(60) Divisional application:
20210819.7

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
15151030.2 / 2 933 252
10733116.7 / 2 454 250

(73) Proprietor: **Gilead Sciences, Inc.**
Foster City, CA 94404 (US)

(72) Inventors:
• **CORKEY, Britton**
Foster City, CA 94404 (US)
• **GRAUPE, Michael**
Pacifica CA 94044 (US)
• **KOCH, Keith**
Erie CO 80516 (US)
• **MELVIN, Lawrence S.**
Longmont CO 80504 (US)
• **NOTTE, Gregory**
San Mateo CA 9441 (US)

(74) Representative: **Wallace, Sheila Jane**
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW (GB)

(56) References cited:
EP-A1- 2 058 309

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).